Giá của Zymeworks Inc. là bao nhiêu (ZYME)

Giá của Zymeworks Inc. (ZYME) là $29.33

Mũ thị trường của Zymeworks Inc. là gì (ZYME)

Giới hạn thị trường của Zymeworks Inc. (ZYME) là $2.16B

Doanh thu Zymeworks Inc. (ZYME)

Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.

Năm	Doanh thu	Thay đổi
Không đủ dữ liệu cho ngày được cung cấp.

Năm

Doanh thu

Thay đổi

Không đủ dữ liệu cho ngày được cung cấp.

Công ty	Doanh thu	Chênh lệch doanh thu	Quốc gia
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
CSL Limited CSL.AX	$15.74B	-	AU
Moderna, Inc. MRNA.US	$2.23B	-	US
Lonza Group AG LONN.SW	-	-	CH

Công ty

Doanh thu

Chênh lệch doanh thu

Quốc gia